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Abstract
Bernard-Soulier syndrome (BSS), also known as Hemorrhagiparous thrombocytic dystrophy, is a
hereditary bleeding disorder affecting the megakaryocyte/platelet lineage and characterized by
bleeding tendency, giant blood platelets and low platelet counts. This syndrome is extremely rare
as only ~100 cases have been reported in the literature. Clinical manifestations usually include
purpura, epistaxis, menorrhagia, gingival and gastrointestinal bleeding. The syndrome is transmitted
as an autosomal recessive trait. The underlying defect is a deficiency or dysfunction of the
glycoprotein GPIb-V-IX complex, a platelet-restricted multisubunit receptor required for normal
primary hemostasis. The GPIb-V-IX complex binds von Willebrand factor, allowing platelet
adhesion and platelet plug formation at sites of vascular injury. Genes coding for the four subunits
of the receptor, GPIBA, GPIBB, GP5 and GP9, map to chromosomes 17p12, 22q11.2, 3q29, and 3q21,
respectively. Defects have been identified in GPIBA, GPIBB, and GP9 but not in GP5. Diagnosis is
based on a prolonged skin bleeding time, the presence of a small number of very large platelets
(macrothrombocytopenia), defective ristocetin-induced platelet agglutination and low or absent
expression of the GPIb-V-IX complex. Prothrombin consumption is markedly reduced. The
prognosis is usually good with adequate supportive care but severe bleeding episodes can occur
with menses, trauma and surgical procedures. Treatment of bleeding or prophylaxis during surgical
procedures usually requires platelet transfusion.
Disease name and synonyms
Bernard-Soulier syndrome (BSS)
Hemorrhagiparous thrombocytic dystrophy
Congenital hemorrhagiparous thrombocytic dystrophy
Definition and diagnostic criteria
The Bernard-Soulier syndrome (BSS) is an autosomal
recessive disease associated with bleeding tendency, giant
blood platelets and low platelet counts. The defect is
restricted to the megakaryocyte/platelet lineage.
Congenital platelet disorders are often difficult to distin-
guish on the basis of clinical manifestations and require
specialized laboratory tests. Functional analysis of platelet
suspensions by aggregometry is needed to differentiate
BSS from other rare inherited disorders accompanied by
macrothrombocytopenia, such as the May-Hegglin,
Sebastian, Fechtner and Epstein's syndromes [1]. A firm
diagnosis calls for conjunction of increased bleeding
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times, macrothrombocytopenia, defective ristocetin-
induced agglutination and low or absent levels of platelet
GPIb-V-IX (CD42a-d) by flow cytometry.
Epidemiology
This syndrome is extremely rare as only ~100 cases have
been reported in published articles, mostly in the popula-
tions of Japan, Europe, and North America. Prevalence
has been estimated at less than 1/1,000,000 but is proba-
bly higher due to misdiagnosis and underreporting. This
low frequency could probably be explained by the fact
that the affected genes are very compact being interrupted
by only 1 or 2 introns.
Clinical description
In 1948, Jean Bernard and Jean-Pierre Soulier [2], two
French hematologists, described a young male patient
who had a severe bleeding defect with a prolonged bleed-
ing time, a low platelet count with very large platelets
(macrothrombocytopenia). In view of these defects, they
named the disorder "Dystrophie thrombocytaire-hémor-
ragipare congénitale" (Hemorrhagiparous thrombocytic
dystrophy). Additional cases presenting with an identical
disorder, mostly transmitted as an autosomal recessive
trait and often associated with consanguinity, have been
subsequently reported [3,4]. In the literature, the disease
is now commonly referred to as Bernard-Soulier syn-
drome (BSS). In most cases, bleeding symptoms manifest
rapidly after birth or during early childhood. Clinical
manifestations usually include purpura, epistaxis, gingival
bleeding and menorrhagia, and more rarely gastrointesti-
nal bleeding and hematuria. Severe bleeding episodes are
associated with trauma and surgical procedures such as
tonsillectomy, appendectomy, splenectomy, or occur dur-
ing dental extractions and menses. However, the severity
and frequency of bleeding vary between individuals.
Bleeding mainly affects mucocutaneous tissues, and
major hematomas are very rarely observed.
Etiology
Defects in three genes give rise to the typical clinical fea-
tures and platelet anomalies associated with BSS. This is
due to the multisubunit nature of the affected GPIb-V-IX
receptor, whose structure is shown in Figure 1. The main
function of the GPIb-V-IX complex is to ensure normal
primary hemostasis by initiating platelet adhesion at sites
of vascular injury [5]. Adhesion is brought by its binding
to von Willebrand factor, itself captured from plasma by
subendothelial collagen [6]. Four distinct transmembrane
proteins, GPIbα (MW 135 kDa), GPIbβ (MW 26 kDa),
GPIX (MW 20 kDa) and GPV (MW 82 kDa) assemble to
form the functional receptor at the surface of bone mar-
row megakaryocytes, the precursors of mature circulating
platelets [7]. GPIbα, GPIbβ, and GPIX are closely associ-
ated and are all required for efficient biosynthesis of the
receptor [8]. A lack of a single subunit dramatically
decreases surface expression of the whole complex. GPV is
more loosely associated and its absence does neither pre-
vent expression, nor von Willebrand factor binding func-
tion. The four subunits are separately encoded by genes
mapping to chromosomes 17p12 (GPIBA), 22q11.2
(GPIBB), 3q29(GP5) and 3q21 (GP9) [9-15]. The four
genes belong to the leucine-rich family of proteins and are
exclusively expressed in platelets under physiological con-
ditions. They have a simple structure with the coding
sequence contained within a single exon, except for GPIBB
which contains an intron of 10 bases after the start codon.
To date, 47 different genetic defects associated to the BSS
have been identified [see Additional file 1]. A Bernard-
Soulier registry can also be found at Bernard-Soulier syn-
drome web site [16]. Defects are due to mutations in
GPIBA (20 mutations), which is the largest subunit and
bears the von Willebrand binding site, in GPIBB  (16
mutations) and in GP9 (11 mutations). The defects can be
separated into three major classes: 1) missense mutations
or short in-frame deletions which rarely give rise to nor-
mal or slightly decreased expression of a dysfunctional
receptor or more often to an abnormal/unstable complex
with strongly decreased surface expression; 2) nonsense
mutations resulting in smaller subunits that typically lack
the transmembrane domain; 3) frameshift insertions or
deletions leading to a novel polypeptide sequence and
often to a premature stop. In very few cases, a single muta-
tion, like in some GPIbα  and GPIX mutants, affects
mainly the function of the receptor, which is at least par-
tially expressed in giant platelets. Most of the defects are
unique to a single individual or family. One exception is
the GP9 Asn45Ser mutation, which has been reported in
The platelet GPIb-V-IX complex Figure 1
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several families from different countries, probably as a
result of a founder effect [17]. The Ala156Val mutation
also occurs frequently in the Italian population, with an
apparent dominant transmission leading to macrothrom-
bocytopenia in heterozygote individuals [18]. Several
mutations combining a BSS phenotype and the DiGeorge/
Velo-cardio-facial syndrome (VCF) have been reported. In
these cases, one allele carried a mutated GPIBB  gene,
while the other allele had the large deletion of the chro-
mosomal region 22q11.2, containing the GPIBB  gene,
typical of the Di George/VCF defect [19].
Several polymorphisms have been reported especially in
the GPIBA gene. They include silent mutations, a missense
mutation which gives rise to an alloantigen and a variable
number of tandem repeat (VNTR) polymorphism [20]. To
date, none of these polymorphisms have been linked to
anomalies in receptor expression or function.
Rare gain of function mutations of GPIBA  give rise to
platelet-type von Willebrand disease, a clinical entity dis-
tinct from BSS. The condition resembles type IIB von Wil-
lebrand disease due to clearance of plasma von
Willebrand factor by aggregated platelets. Three missense
mutations in a disulfide loop flanking the leucine-rich
domain and a 9 amino acid deletion in the macroglyco-
peptide have been reported in these patients [21-24].
Diagnostic methods
Skin bleeding times in BSS are moderately (5–10 min) to
severely (>20 min) prolonged. A constant feature is the
presence of a small number of very large platelets with a
rounded shape (main volume 11–16 μm3; diameter 4–10
μm). The initial laboratory test should therefore include
blood cell counts and examination of blood smears. Plate-
let counts typically range from 20,000 to 100,000/μl.
Manual counting is required for an accurate determina-
tion as the very large platelets in BSS are often mistaken
for lymphocytes in automatic counters. The distinctive
abnormality of BSS platelets is an isolated defect in ris-
tocetin-induced agglutination. Unlike the defect in von
Willebrand disease, this anomaly is not corrected by the
addition of normal plasma. Levels of FVIII-von Wille-
brand complex are assessed. Aggregation responses to
agonists such as ADP or collagen are normal, however
decreased responses to thrombin can be observed. A
marked defect in prothrombin consumption is constantly
observed and may be useful for the diagnosis: it is attrib-
uted to a defective binding of FXI due to a lack of GPIb
[25], and to a decrease in GPIb-fibrin-dependent
thrombin generation [26,27]. Flow cytometry analysis
using a panel of specific monoclonal antibodies (CD42 a-
d) will confirm this diagnosis. Additional tests in special-
ized research units may include platelet glycoprotein anal-
ysis by SDS-polyacrylamide gel separation and
immunoblotting, and finally, study of genetic abnormali-
ties.
Differential diagnosis
BSS belongs to a heterogeneous group of rare inherited
diseases characterized by a reduced number of platelets
(thrombocytopenia). A published diagnostic algorithm
should facilitate differential diagnosis of BSS [28]. For
example, presence of small platelets is typical of Wiscott-
Aldrich syndrome and X-linked thrombocytopenia. Giant
platelets associated with neutrophil inclusions will orient
toward MYH9-related diseases (May-Hegglin, Sebastian,
Fechtner, and Epstein syndromes). Other parameters will
help diagnose macrothrombocytopenia in Di George,
Gray platelet, Montreal and Paris-Trousseau syndromes.
Finally, some cases of heterozygous BSS can also exhibit
macrothrombocytopenia.
BSS is difficult to be distinguished on the basis of clinical
manifestations only and has often been misdiagnosed as
idiopathic thrombocytopenic purpura (ITP), an immuno-
logical disorder, and treated unsuccessfully with steroids
or splenectomy.
Genetic counseling
Genetic counseling should follow the standards estab-
lished for all autosomal recessive diseases.
Antenatal diagnosis
Prenatal diagnosis is theoretically feasible when the
genetic defect has been identified in a particular kindred.
This is probably not justified as the syndrome rarely gives
rise to life threatening bleeding. With a good prophylaxis,
a fairly normal quality of life can be maintained. In addi-
tion, cord blood or chorion villus sampling bear a high
risk of bleeding and premature abortion.
Management
Therapeutic approaches include both general and specific
treatment of bleeding. Patients should be warned to avoid
traumas, antiplatelet medication such as aspirin, to main-
tain adequate dental hygiene and to use contraceptive in
female at puberty. Treatment of bleeding or prophylaxis
during surgical procedures usually requires blood or
platelet transfusion with the associated risk of developing
antiplatelet alloantibodies. Desmopressin and rFVIIa
administration have been shown to shorten the bleeding
time in some patients. In rare cases of patients with life-
threatening disorders, bone-marrow or umbilical-cord
hematopoietic stem cell transplantation may be consid-
ered [29]. As a rather simple genetic defect, BSS could be
a candidate for future gene replacement therapy using
virally transduced megakaryocyte progenitors.Orphanet Journal of Rare Diseases 2006, 1:46 http://www.OJRD.com/content/1/1/46
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Prognosis
With a good education, adequate care and prevention of
trauma, patients can live a fairly normal life. Nevertheless,
possible occurrence of severe bleeding in case of trauma
and surgical intervention should always be kept in mind
and treated adequately.
Unresolved questions
To date, no BSS patient has been identified with a muta-
tion of the GPV subunit but existence of such defects can-
not be ruled out, and they could potentially result in
variant or mild forms of BSS.
As for other platelet deficiencies, it is difficult to correlate
genetic defects with propensity to bleed and severity of
bleeding.
The molecular and cellular mechanisms responsible for
the several platelet defects encountered in BSS are still
largely unknown. An explanation for their enlarged plate-
lets and low platelet counts is probably related to defec-
tive megakaryocytopoiesis but such studies are difficult to
conduct in BSS patients. Additionally, platelet functional
studies  in vivo and evaluation of a putative protection
against thrombosis are not amenable in BSS patients.
Finally, there is no clear explanation for the abnormal
prothrombin consumption in this pathology. Mouse
models of BSS are now available with deletions of the




1. Nurden AT: Qualitative disorders of platelets and megakary-
ocytes.  J Thromb Haemost 2005, 3:1773-1782.
2. Bernard J, Soulier JP: Sur une nouvelle variété de dystrophie
thrombocytaire-hémorragipare congénitale.  Sem Hop Paris
1948, 24:3217-3222.
3. de la Salle C, Lanza F, Cazenave JP: Biochemical and molecular
basis of Bernard-Soulier syndrome: a review.  Nouv Rev Fr
Hematol 1995, 37:215-222.
4. Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC: Bernard-
Soulier syndrome.  Blood 1998, 91:4397-4418.
5. Clemetson KJ: Platelet receptors and their role in diseases.
Clin Chem Lab Med 2003, 41:253-260.
6. Ruggeri ZM: Von Willebrand factor, platelets and endothelial
cell interactions.  J Thromb Haemost 2003, 1:1335-1343.
7. Andrews RK, Shen Y, Gardiner EE, Dong JF, Lopez JA, Berndt MC:
The glycoprotein Ib-IX-V complex in platelet adhesion and
signaling.  Thromb Haemost 1999, 82:357-364.
8 . U l s e m e r  P ,  S t r a s s e l  C ,  B a a s  M J ,  S a l a m e r o  J ,  C h a s s e r o t - G o l a z  S ,
Cazenave JP, de la Salle C, Lanza F: Biosynthesis and intracellular
post-translational processing of normal and mutant platelet
glycoprotein GPIb-IX.  Biochem J 2001, 358:295-303.
9. Lopez JA, Chung DW, Fujikawa K, Hagen FS, Papayannopoulou T,
Roth GJ: Cloning of the alpha chain of human platelet glyco-
protein Ib: a transmembrane protein with homology to leu-
cine-rich alpha 2-glycoprotein.  Proc Natl Acad Sci USA 1987,
84:5615-5619.
10. Wenger RH, Wicki AN, Kieffer N, Adolph S, Hameister H, Clemet-
son KJ: The 5' flanking region and chromosomal localization
of the gene encoding human platelet membrane glycopro-
tein Ib alpha.  Gene 1989, 85:517-524.
11. Lopez JA, Chung DW, Fujikawa K, Hagen FS, Davie EW, Roth GJ:
The alpha and beta chains of human platelet glycoprotein Ib
are both transmembrane proteins containing a leucine-rich
amino acid sequence.  Proc Natl Acad Sci USA 1988, 85:2135-2139.
12. Yagi M, Edelhoff S, Disteche CM, Roth GJ: Structural characteri-
zation and chromosomal location of the gene encoding
human platelet glycoprotein Ib beta.  J Biol Chem 1994,
269:17424-17427.
13. Lanza F, Morales M, de la Salle C, Cazenave JP, Clemetson KJ, Shi-
momura T, Phillips DR: Cloning and characterization of the
gene encoding the human platelet glycoprotein V. A mem-
ber of the leucine-rich glycoprotein family cleaved during
thrombin-induced platelet activation.  J Biol Chem 1993,
268:20801-20807.
14. Hickey MJ, Deaven LL, Roth GJ: Human platelet glycoprotein IX.
Characterization of cDNA and localization of the gene to
chromosome 3.  FEBS Lett 1990, 274:189-192.
15. Yagi M, Edelhoff S, Disteche CM, Roth GJ: Human platelet glyco-
proteins V and IX: mapping of two leucine-rich glycoprotein
genes to chromosome 3 and analysis of structures.  Biochemis-
try 1995, 34:16132-16137.
16. Bernard-Soulier Syndrome   [http://www.bernardsoulier.org]
17. Liang HP, Morel-Kopp MC, Clemetson JM, Clemetson KJ, Kekomaki
R, Kroll H, Michaelides K, Tuddenham EG, Vanhoorelbeke K, Ward
CM:  A common ancestral glycoprotein (GP) 9 1828A>G
(Asn45Ser) gene mutation occurring in European families
from Australia and Northern Europe with Bernard-Soulier
Syndrome (BSS).  Thromb Haemost 2005, 94:599-605.
18. Savoia A, Balduini CL, Savino M, Noris P, Del Vecchio M, Perrotta S,
Belletti S, Poggi , Iolascon A: Autosomal dominant macrothrom-
bocytopenia in Italy is most frequently a type of hetero-
zygous Bernard-Soulier syndrome.  Blood 2001, 97:1330-1305.
19. Budarf ML, Konkle BA, Ludlow LB, Michaud D, Li M, Yamashiro DJ,
McDonald-McGinn D, Zackai EH, Driscoll DA: Identification of a
patient with Bernard-Soulier syndrome and a deletion in the
DiGeorge/velo-cardio-facial chromosomal region in 22q11.2.
Hum Mol Genet 1995, 4:763-766.
20. Lopez JA, Ludwig EH, McCarthy BJ: Polymorphism of human
glycoprotein Ib alpha results from a variable number of tan-
dem repeats of a 13-amino acid sequence in the mucin-like
macroglycopeptide region. Structure/function implications.
J Biol Chem 1992, 267:10055-10061.
21. Miller JL, Cunningham D, Lyle VA, Finch CN: Mutation in the gene
encoding the alpha chain of platelet glycoprotein Ib in plate-
let-type von Willebrand disease.  Proc Natl Acad Sci USA 1991,
88:4761-4765.
22. Russell SD, Roth GJ: Pseudo-von Willebrand disease: a muta-
tion in the platelet glycoprotein Ib alpha gene associated
with a hyperactive surface receptor.  Blood 1993, 81:1787-1791.
23. Matsubara Y, Murata M, Sugita K, Ikeda Y: Identification of a novel
point mutation in platelet glycoprotein Ibalpha, Gly to Ser at
residue 233, in a Japanese family with platelet-type von Wil-
lebrand disease.  J Thromb Haemost 2003, 1:2198-2205.
24. Othman M, Notley C, Lavender FL, White H, Byrne CD, Lillicrap D,
O'Shaughnessy DF: Identification and functional characteriza-
tion of a novel 27-bp deletion in the macroglycopeptide-cod-
ing region of the GPIBA gene resulting in platelet-type von
Willebrand disease.  Blood 2005, 105:4330-4336.
25. Baglia FA, Badellino KO, Li CQ, Lopez JA, Walsh PN: Factor XI
binding to the platelet glycoprotein Ib-IX-V complex pro-
Additional file 1
Genetic defects in Bernard-Soulier syndrome. This is a table that repre-
sents the genetic defects in Bernard-Soulier syndrome and corresponding 
references.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1750-
1172-1-46-S1.doc]Orphanet Journal of Rare Diseases 2006, 1:46 http://www.OJRD.com/content/1/1/46
Page 5 of 6
(page number not for citation purposes)
motes factor XI activation by thrombin.  J Biol Chem 2002,
18:1662-1668.
26. Beguin S, Kumar R, Keularts I, Seligsohn U, Coller BS, Hemker HC:
Fibrin-dependent platelet procoagulant activity requires
GPIb receptors and von Willebrand factor.  Blood 1999,
93:564-570.
27. Al Dieri R, Bellucci S, Beguin S, Hemker HC, Caen J: Defective
vWF-Fibrin-GPIb interaction causes impaired prothrombin
consumption in Bernard-Soulier Syndrome [abstract].  J
Thromb Haemost 2003:754.
28. Balduini CL, Cattaneo M, Fabris F, Gresele P, Iolascon A, Pulcinelli FM,
Savoia A: Inherited thrombocytopenias: a proposed diagnos-
tic algorithm from the Italian Gruppo di Studio delle Pias-
trine.  Haematologica 2003, 88:582-592.
29. Locatelli F, Rossi G, Balduini C: Hematopoietic stem-cell trans-
plantation for the Bernard-Soulier syndrome.  Ann Intern Med
2003, 138:79.
30. Kunishima S, Imai T, Hamaguchi M, Saito H: Novel heterozygous
missense mutation in the second leucine rich repeat of
GPIba affects GPIb/IX/V expression and results in macro-
thrombocytopenia in a patient initially misdiagnosed with
idiopathic thrombocytopenic purpura.  Eur J Haematol 2006,
76:348-355.
31. Miller JL, Lyle VA, Cunningham D: Mutation of leucine-57 to phe-
nylalanine in a platelet glycoprotein Ib alpha leucine tandem
repeat occurring in patients with an autosomal dominant
variant of Bernard-Soulier disease.  Blood 1992, 79:439-446.
32. Kenny D, Jonsson OG, Morateck PA, Montgomery RR: Naturally
occurring mutations in glycoprotein Ib that result in defec-
tive ligand binding and synthesis of a truncated protein.  Blood
1998, 92:175-183.
33. Li C, Martin SE, Roth GJ: The genetic defect in two well-studied
cases of Bernard-Soulier syndrome: a point mutation in the
fifth leucine-rich repeat of platelet glycoprotein Ib alpha.
Blood 1995, 86:3805-3814.
34. Antonucci JV, Martin ES, Hulick PJ, Joseph A, Martin SE: Bernard-
Soulier syndrome: Common ancestry in two African Ameri-
can families with the GP Ib Leu129Pro mutation.  Am J Hema-
tol 2000, 65:141-148.
35. Koskela S, Partanen J, Salmi TT, Kekomaki R: Molecular character-
ization of two mutations in platelet glycoprotein (GP) Ib
alpha in two Finnish Bernard-Soulier syndrome families.  Eur
J Haematol 1999, 62:160-168.
36. Ware J, Russell SR, Marchese P, Murata M, Mazzucato M, De Marco
L, Ruggeri ZM: Point mutation in a leucine-rich repeat of plate-
let glycoprotein Ib alpha resulting in the Bernard-Soulier
syndrome.  J Clin Invest 1993, 92:1213-1220.
37. Margaglione M, D'Andrea G, Grandone E, Brancaccio V, Amoriello A,
Di Minno G: Compound heterozygosity (554–589 del, C515-T
transition) in the platelet glycoprotein Ib alpha gene in a
patient with a severe bleeding tendency.  Thromb Haemost
1999, 81:486-492.
38. de la Salle C, Baas MJ, Lanza F, Schwartz A, Hanau D, Chevalier J,
Gachet C, Briquel ME, Cazenave JP: A three-base deletion
removing a leucine residue in a leucine-rich repeat of plate-
let glycoprotein Ib alpha associated with a variant of Ber-
nard-Soulier syndrome (Nancy I).  Br J Haematol 1995,
89:386-396.
39. Ulsemer P, Lanza F, Baas MJ, Schwartz A, Ravanat C, Briquel ME,
Cranmer S, Jackson S, Cazenave JP, de la Salle C: Role of the leu-
cine-rich domain of platelet GPIbalpha in correct post-trans-
lational processing – the Nancy I Bernard-Soulier mutation
expressed on CHO cells.  Thromb Haemost 2000, 84:104-111.
40. Simsek S, Noris P, Lozano M, Pico M, von dem Borne AE, Ribera A,
Gallardo D: Cys209 Ser mutation in the platelet membrane
glycoprotein Ib alpha gene is associated with Bernard-Soul-
ier syndrome.  Br J Haematol 1994, 88:839-844.
41. Gonzalez-Manchon C, Larrucea S, Pastor AL, Butta N, Arias-Salgado
EG, Ayuso MS, Parrilla R: Compound heterozygosity of the
GPIbalpha gene associated with Bernard-Soulier syndrome.
Thromb Haemost 2001, 86:1385-1391.
42. Ware J, Russell SR, Vicente V, Scharf RE, Tomer A, McMillan R, Rug-
geri ZM: Nonsense mutation in the glycoprotein Ib alpha cod-
ing sequence associated with Bernard-Soulier syndrome.
Proc Natl Acad Sci USA 1990, 87:2026-2030.
43. Kunishima S, Miura H, Fukutani H, Yoshida H, Osumi K, Kobayashi S,
Ohno R, Naoe T: Bernard-Soulier syndrome Kagoshima: Ser
444-->stop mutation of glycoprotein (GP) Ib alpha resulting
in circulating truncated GPIb alpha and surface expression of
GPIb beta and GPIX.  Blood 1994, 84:3356-3362.
44. Holmberg L, Karpman D, Nilsson I, Olofsson T: Bernard-Soulier
syndrome Karlstad: Trp 498-->Stop mutation resulting in a
truncated glycoprotein Ib alpha that contains part of the
transmembranous domain.  Br J Haematol 1997, 98:57-63.
45. Li C, Pasquale DN, Roth GJ: Bernard-Soulier syndrome with
severe bleeding: absent platelet glycoprotein Ib alpha due to
a homozygous one-base deletion.  Thromb Haemost 1996,
76:670-674.
46. Afshar-Kharghan V, Craig FE, Lopez JA: Bernard-Soulier syn-
drome in a patient doubly heterozygous for two frameshift
mutations in the glycoprotein ib alpha gene.  Br J Haematol
2000, 110:919-924.
47. Simsek S, Noris P, Lozano M, Pico M, von dem Borne AE, Ribera A,
Gallardo D: Cys209 Ser mutation in the platelet membrane
glycoprotein Ib alpha gene is associated with Bernard-Soul-
ier syndrome.  Br J Haematol 1994, 88:839-844.
48. Kanaji T, Okamura T, Kurolwa M, Noda M, Fujimura K, Kuramoto A,
Sano M, Nakano S, Niho Y: Molecular and genetic analysis of
two patients with Bernard-Soulier syndrome – identification
of new mutations in glycoprotein Ib alpha gene.  Thromb Hae-
most 1997, 77:1055-1061.
49. Noda M, Fujimura K, Takafuta T, Shimomura T, Fujimoto T,
Yamamoto N, Tanoue K, Arai M, Suehiro A, Kakishita E, Shimasaki A,
Kuramoto A: Heterogeneous expression of glycoprotein Ib, IX
and V in platelets from two patients with Bernard-Soulier
syndrome caused by different genetic abnormalities.  Thromb
Haemost 1995, 74:1411-1415.
50. Noda M, Fujimura K, Takafuta T, Shimomura T, Fujii T, Katsutani S,
Fujimoto T, Kuramoto A, Yamazaki T, Mochizuki T, Matsuzaki M,
Sano M: A point mutation in glycoprotein IX coding sequence
(Cys73 (TGT) to Tyr(TAT)) causes impaired surface expres-
sion of GPIb/IX/V complex in two families with Bernard-
Soulier syndrome.  Thromb Haemost 1996, 76:874-878.
51. Mitsui T, Yokoyama S, Yazaki N, Hayashi T, Suzuki K, Shimizu Y,
Kawakami T, Kanazawa C, Katsuura M, Ikegami T, Hayasaka K:
Severe bleeding tendency in a patient with Bernard-Soulier
syndrome associated with a homozygous single base pair
deletion in the gene coding for the human platelet glycopro-
tein Ibalpha.  J Pediatr Hematol Oncol 1998, 20:246-251.
52. Afshar-Kharghan V, Lopez JA: Bernard-Soulier syndrome caused
by a dinucleotide deletion and reading frameshift in the
region encoding the glycoprotein Ib alpha transmembrane
domain.  Blood 1997, 90:2634-2643.
53. Kenny D, Newman PJ, Morateck PA, Montgomery RR: A dinucle-
otide deletion results in defective membrane anchoring and
circulating soluble glycoprotein Ib alpha in a novel form of
Bernard-Soulier syndrome.  Blood 1997, 90:2626-2633.
54. Gonzalez-Manchon C, Butta N, Iruin G, Alonso S, Ayuso MS, Parrilla
R: Disruption of the Cys5–Cys7 disulfide bridge in the plate-
let glycoprotein Ibbeta prevents the normal maturation and
surface exposure of GPIb-IX complexes.  Thromb Haemost
2003, 90:456-464.
55. Kunishima S, Naoe T, Kamiya T, Saito H: Novel heterozygous mis-
sense mutation in the platelet glycoprotein Ib beta gene
associated with isolated giant platelet disorder.  Am J Hematol
2001, 68:249-255.
56. Hillmann A, Nurden A, Nurden P, Combrie R, Claeyssens S, Moran
N, Kenny D: A novel hemizygous Bernard-Soulier Syndrome
(BSS) mutation in the amino terminal domain of glycopro-
tein (GP) Ibbeta – platelet characterization and transfection
studies.  Thromb Haemost 2002, 88:1026-1032.
57. Strassel C, Pasquet JM, Alessi MC, Juhan-Vague I, Chambost H, Com-
brie R, Nurden P, Bas MJ, De La Salle C, Cazenave JP, Lanza F, Nurden
AT: A novel missense mutation shows that GPIbbeta has a
dual role in controlling the processing and stability of the
platelet GPIb-IX adhesion receptor.  Biochemistry 2003,
42:4452-4462.
58. Kunishima S, Tomiyama Y, Honda S, Fukunishi M, Hara J, Inoue C,
Kamiya T, Saito H: Homozygous Pro74-->Arg mutation in the
platelet glycoprotein Ibbeta gene associated with Bernard-
Soulier syndrome.  Thromb Haemost 2000, 84:112-117.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Orphanet Journal of Rare Diseases 2006, 1:46 http://www.OJRD.com/content/1/1/46
Page 6 of 6
(page number not for citation purposes)
59. Kurokawa Y, Ishida F, Kamijo T, Kunishima S, Kenny D, Kitano K,
Koike K: A missense mutation (Tyr88 to Cys) in the platelet
membrane glycoprotein Ibbeta gene affects GPIb/IX com-
plex expression – Bernard-Soulier syndrome in the
homozygous form and giant platelets in the heterozygous
form.  Thromb Haemost 2001, 86:1249-1256.
60. Kunishima S, Lopez JA, Kobayashi S, Imai N, Kamiya T, Saito H, Naoe
T: Missense mutations of the glycoprotein (GP) Ib beta gene
impairing the GPIb alpha/beta disulfide linkage in a family
with giant platelet disorder.  Blood 1997, 89:2404-2412.
61. Tang J, Stern-Nezer S, Liu PC, Matyakhina L, Riordan M, Luban NL,
Steinbach PJ, Kaler SG: Mutation in the leucine-rich repeat C-
flanking region of platelet glycoprotein Ib beta impairs
assembly of von Willebrand factor receptor.  Thromb Haemost
2004, 92:75-88.
62. Kunishima S, Yamazaki T, Matsushita T, Sako M, Hamaguchi M, Saito
H: Variant Bernard-Soulier syndrome caused by compound
heterozygous mutations in the GPIb beta gene [abstract].
Platelets 2004, 15:374-375.
63. de la Salle C, Lanza F, Caen J, Nurden P, Nurden AT, Juhan I, Briquel
ME, Ternisien C, Conard J, Cazenave JP: Molecular characteriza-
tion of five different mutations in patients with Bernard-
Soulier bleeding disorder. Central role of platelet GPIbb and
GPIX in GPIb-IX-V expression [abstract].  Thromb Haemost
1997:68.
64. Moran N, Morateck PA, Deering A, Ryan M, Montgomery RR, Fitzger-
ald DJ, Kenny D: Surface expression of GPIb alpha is depend-
ent on GPIb beta: evidence from a novel mutation causing
Bernard-Soulier syndrome.  Blood 2000, 96:532-539.
65. Kunishima S, Matsushita T, Ito T, Kamiya T, Saito H: Novel non-
sense mutation in the platelet glycoprotein Ibbeta gene
associated with Bernard-Soulier syndrome.  Am J Hematol
2002, 71:279-284.
66. Kenny D, Morateck PA, Gill JC, Montgomery RR: The critical inter-
action of glycoprotein (GP) IBbeta with GPIX-a genetic
cause of Bernard-Soulier syndrome.  Blood 1999, 93:2968-2975.
67. Watanabe R, Ishibashi T, Saitoh Y, Shichishima T, Maruyama Y,
Enomoto Y, Handa M, Oda A, Ambo H, Murata M, Ikeda Y: Bernard-
soulier syndrome with a homozygous 13 base pair deletion
in the signal peptide-coding region of the platelet glycopro-
tein Ib(beta) gene.  Blood Coagul Fibrinolysis 2003, 14:387-394.
68. Strassel C, Alessi MC, Juhan-Vague I, Cazenave JP, Lanza F: A 13 base
pair deletion in the GPIbbeta gene in a second unrelated
Bernard-Soulier family due to slipped mispairing between
direct repeats.  J Thromb Haemost 2004, 2:1663-1665.
69. Strassel C, David T, Eckly A, Baas MJ, Moog S, Ravanat C, Trzeciak
MC, Vinciguerra C, Cazenave JP, Gachet C, Lanza F: Synthesis of
GPIb beta with novel transmembrane and cytoplasmic
sequences in a Bernard-Soulier patient resulting in GPIb-
defective signaling in CHO cells.  J Thromb Haemost 2006,
4:217-228.
70. Ludlow LB, Schick BP, Budarf ML, Driscoll DA, Zackai EH, Cohen A,
Konkle BA: Identification of a mutation in a GATA binding
site of the platelet glycoprotein Ibbeta promoter resulting in
the Bernard-Soulier syndrome.  J Biol Chem 1996,
271:22076-22080.
71. Lanza F, de la Salle C, Baas MJ, Schwartz A, Boval B, Cazenave JP, Caen
JP: A Leu7Pro mutation in the signal peptide of platelet glyc-
oprotein (GP)IX in a case of Bernard-Soulier syndrome abol-
ishes surface expression of the GPIb-V-IX complex.  Br J
Haematol 2002, 118:260-266.
72. Rivera CE, Villagra J, Riordan M, Williams S, Lindstrom KJ, Rick ME:
Identification of a new mutation in platelet glycoprotein IX
(GPIX) in a patient with Bernard-Soulier syndrome.  Br J Hae-
matol 2001, 112:105-108.
73. Wright SD, Michaelides K, Johnson DJ, West NC, Tuddenham EG:
Double heterozygosity for mutations in the platelet glyco-
protein IX gene in three siblings with Bernard-Soulier syn-
drome.  Blood 1993, 81:2339-2347.
74. Noris P, Arbustini E, Spedini P, Belletti S, Balduini CL: A new variant
of Bernard-Soulier syndrome characterized by dysfunctional
glycoprotein (GP) Ib and severely reduced amounts of GPIX
and GPV.  Br J Haematol 1998, 103:1004-1013.
75. Clemetson JM, Kyrle PA, Brenner B, Clemetson KJ: Variant Ber-
nard-Soulier syndrome associated with a homozygous muta-
tion in the leucine-rich domain of glycoprotein IX.  Blood 1994,
84:1124-1131.
76. Donner M, Karpman D, Kristoffersson AC, Winqvist I, Holmberg L:
Recurrent mutation Asn45-->Ser of glycoprotein IX in Ber-
nard-Soulier syndrome.  Eur J Haematol 1996, 57:178-179.
77. Koskela S, Javela K, Jouppila J, Juvonen E, Nyblom O, Partanen J,
Kekomaki R: Variant Bernard-Soulier syndrome due to
homozygous Asn45Ser mutation in the platelet glycoprotein
(GP) IX in seven patients of five unrelated Finnish families.
Eur J Haematol 1999, 62:256-264.
78. Vanhoorelbeke K, Schlammadinger A, Delville JP, Handsaeme J, Van-
decasteele G, Vauterin S, Pradier O, Wijns W, Deckmyn H: Occur-
rence of the Asn45Ser mutation in the GPIX gene in a
Belgian patient with Bernard Soulier syndrome.  Platelets
2001, 12:114-120.
79. Sachs UJ, Kroll H, Matzdorff AC, Berghofer H, Lopez JA, Santoso S:
Bernard-Soulier syndrome due to the homozygous Asn-
45Ser mutation in GPIX: an unexpected, frequent finding in
Germany.  Br J Haematol 2003, 123:127-131.
80. Drouin J, Carson NL, Laneuville O: Compound heterozygosity
for a novel nine-nucleotide deletion and the Asn45Ser mis-
sense mutation in the glycoprotein IX gene in a patient with
Bernard-Soulier syndrome.  Am J Hematol 2005, 78:41-48.
81. Suzuki K, Hayashi T, Yahagi A, Akiba J, Tajima K, Satoh S, Sasaki H:
Novel point mutation in the leucine-rich motif of the platelet
glycoprotein IX associated with Bernard-Soulier syndrome.
Br J Haematol 1997, 99:794-800.
82. Suzuki K, Hayashi T, Akiba J, Satoh S, Kato T: Phenotypic conse-
quence of the gene abnormality in the platelet glycoprotein
I X  g e n e  o b s e r v e d  i n  a  p a t i ent with Bernard-Soulier syn-
drome through mammalian cell expression system.  Thromb
Res 1999, 95:295-302.
83. Kunishima S, Tomiyama Y, Honda S, Kurata Y, Kamiya T, Ozawa K,
Saito H: Cys97-->Tyr mutation in the glycoprotein IX gene
associated with Bernard-Soulier syndrome.  Br J Haematol
1999, 107:539-545.
84. Wang Z, Zhao X, Duan W, Fu J, Lu M, Wang G, Bai X, Ruan C: A
novel mutation in the transmembrane region of glycopro-
tein IX associated with Bernard-Soulier syndrome.  Thromb
Haemost 2004, 92:606-613.
85. Garner C, Best S, Menzel S, Rooks H, Spector TD, Thein SL: Two
candidate genes for low platelet count identified in an Asian
Indian kindred by genome-wide linkage analysis: glycopro-
tein IX and thrombopoietin.  Eur J Hum Genet 2006, 14:101-108.
86. Iwanaga M, Kunishima S, Ikeda S, Tomonaga M, Naoe T: Vulnerable
mutation Trp126-->stop of glycoprotein IX in Japanese Ber-
nard-Soulier syndrome.  Eur J Haematol 1998, 60:264-246.